3.835

2.82% 0.105

Revance Therapeutics Inc (RVNC)

Overview News Price History Option Chain Financials Why RVNC Down? Discussions Forecast

Revance Therapeutics Inc stock is traded at $3.835, with a volume of 1.07M. It is up +2.82% in the last 24 hours and down -33.88% over the past month. Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Previous Close:

$3.73

Open:

$3.9

24h Volume:

1.07M

Relative Volume:

0.36

Market Cap:

$391.29M

Revenue:

$234.04M

Net Income/Loss:

$-323.92M

P/E Ratio:

-0.8466

EPS:

-4.53

Net Cash Flow:

$-223.46M

1W Performance:

-4.60%

1M Performance:

-33.88%

6M Performance:

+27.41%

1Y Performance:

-47.03%

1-Day Range:

$3.735

$4.12

1-Week Range:

$3.55

$4.21

52-Week Range:

$2.30

$9.745

Revance Therapeutics Inc Stock (RVNC) Company Profile

Name

Revance Therapeutics Inc

Sector

Healthcare (1180)

Industry

Biotechnology (683)

Phone

(615) 724-7755

Address

1222 DEMONBREUN STREET, NASHVILLE, CA

Employee

597

Twitter

@revance

Next Earnings Date

2024-11-04

Latest SEC Filings

RVNC's Discussions on Twitter

Compare RVNC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RVNC Revance Therapeutics Inc	3.835	391.29M	234.04M	-323.92M	-223.46M	-3.80
VRTX Vertex Pharmaceuticals Inc	459.44	119.71B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	748.16	82.77B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	611.64	37.02B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	249.47	32.26B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.21	28.24B	3.30B	-501.07M	1.03B	-2.1146

Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-29-24	Downgrade	Mizuho	Buy → Neutral
Jan-09-24	Downgrade	Goldman	Buy → Neutral
Aug-16-23	Upgrade	Exane BNP Paribas	Underperform → Neutral
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight
Sep-22-22	Initiated	Goldman	Buy
Oct-25-21	Downgrade	Wells Fargo	Overweight → Equal Weight
Oct-15-20	Reiterated	Needham	Buy
Aug-11-20	Resumed	Mizuho	Buy
Mar-23-20	Downgrade	Goldman	Buy → Neutral
Dec-02-19	Initiated	Goldman	Buy
Oct-30-19	Upgrade	Wells Fargo	Market Perform → Outperform
Jun-11-19	Initiated	Barclays	Overweight
Feb-15-19	Initiated	Wells Fargo	Market Perform
Feb-14-19	Initiated	H.C. Wainwright	Buy
Jan-29-19	Initiated	Stifel	Buy
Nov-16-18	Upgrade	Guggenheim	Neutral → Buy
Sep-17-18	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Apr-20-18	Reiterated	Mizuho	Buy
Mar-27-18	Initiated	Needham	Buy
Mar-05-18	Initiated	Goldman	Buy
Jan-09-18	Downgrade	Guggenheim	Buy → Neutral
Dec-06-17	Initiated	Guggenheim	Buy
Dec-06-17	Reiterated	Mizuho	Buy
Nov-27-17	Initiated	Barclays	Overweight
Nov-17-17	Initiated	Mizuho	Buy
Aug-22-17	Initiated	JMP Securities	Mkt Outperform

View All

Revance Therapeutics Inc Stock (RVNC) Latest News

Nov 29, 2024

Revance delays tender offer commencement to December 3 By Investing.com - Investing.com Australia

Nov 29, 2024

Revance extends tender offer commencement date again By Investing.com - Investing.com Canada

Nov 26, 2024

Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com - MarketBeat

Nov 26, 2024

Nov 21, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, B - GuruFocus.com

Nov 21, 2024

Spasticity Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Jazz Pharmaceuticals, Revance Therapeutics, Ipsen - Barchart

Nov 21, 2024

Nov 20, 2024

Revance Therapeutics sinks amid `going concern' disclosure - MSN

Nov 20, 2024

Alpine Associates Management Inc. Makes New $21.61 Million Investment in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat

Nov 20, 2024

Revance and Crown extend merger offer date to November 26 - Investing.com India

Nov 20, 2024

Revance and Crown extend merger offer date to November 26 By Investing.com - Investing.com Australia

Nov 20, 2024

Revance Therapeutics gains as Crown Labs further extends tender offer - MSN

Nov 20, 2024

Revance Therapeutics jumps after Crown Laboratories tender offer extended again - MSN

Nov 20, 2024

Nov 18, 2024

LMR Partners LLP Acquires New Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat

Nov 18, 2024

Nov 14, 2024

Neurotoxin Market Overall Study Report 2024-2032 | Revance - openPR

Nov 14, 2024

Nov 12, 2024

Revance, Crown Labs Again Extend Tender Offer Start Deadline - MarketWatch

Nov 12, 2024

Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $9.66 Consensus Target Price from Analysts - MarketBeat

Nov 12, 2024

Nov 10, 2024

StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat

Nov 10, 2024

Nov 09, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROIC, PWUP, RVNC on Behalf of Shareholders - GlobeNewswire Inc.

Nov 09, 2024

Nov 08, 2024

Where are the Opportunities in (RVNC) - Stock Traders Daily

Nov 08, 2024

Revance Therapeutics (NASDAQ:RVNC) Given Hold Rating at Needham & Company LLC - MarketBeat

Nov 08, 2024

Revance Therapeutics' (RVNC) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat

Nov 08, 2024